Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Exelixis Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination settings for the pending work.
CHENG, KAREN is the identified busiest examiner. Counsel should retain matter-specific prosecution plans while coordinating terminology and claim strategy across the biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| §112 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHENG, KAREN | 1 | 76.4% | +26.2% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277956 | PYRIDONE COMPOUNDS AND METHODS OF USE | WARD, PAUL V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834799 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | CHENG, KAREN | — |
| 18132124 | Compounds for the Treatment of Kinase-Dependent Disorders | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1622 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18834799 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | CHENG, KAREN | 1623 | §102Other | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18277956 | PYRIDONE COMPOUNDS AND METHODS OF USE | WARD, PAUL V | 1622 | §112 | Final Rejection | — | Pending | Aug 18, 2023 |
| 18132124 | Compounds for the Treatment of Kinase-Dependent Disorders | RAO, PADMAJA S | 1627 | Other | Non-Final OA | — | Pending | Apr 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExelixis Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Karen Cheng has the most, with 1 of Exelixis Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.